Quarterly report pursuant to Section 13 or 15(d)

Deferred Research And Development Arrangement (Details)

v3.10.0.1
Deferred Research And Development Arrangement (Details) - USD ($)
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Dec. 31, 2003
Feb. 05, 2018
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Other income   $ 368,750      
Percentage of licensing revenue         50.00%
Rexgene Biotech Co., Ltd. [Member]          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Research and development arrangement, one-time fee       $ 1,500,000  
Reduction of research and development expenses $ 18,750 $ 6,250 $ 37,500    
Research and development period   20 years      
Other income   $ 368,750      
Maximum [Member]          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Licensing revenue agreement         $ 5,000,000